NO20044592L - Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer - Google Patents

Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer

Info

Publication number: NO20044592L
Authority: NO; Norway
Prior art keywords: kinase inhibitors; compounds useful; aryl ketone; pyrrolotriazine compounds; pyrrolotriazine
Prior art date: 2002-04-23

Application number

NO20044592A

Other languages

English (en)

Norwegian (no)

Inventor

Katerina Leftheris

John Hynes

Alaric Dyckman

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-23

Filing date

2004-10-25

Publication date

2004-11-19

2004-10-25 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2004-11-19 Publication of NO20044592L publication Critical patent/NO20044592L/no

Links

229940043355 kinase inhibitor Drugs 0.000 title abstract 2
239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
-1 Aryl ketone pyrrolotriazine compounds Chemical class 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20044592A 2002-04-23 2004-10-25 Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer NO20044592L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37490702P	2002-04-23	2002-04-23
PCT/US2003/012420 WO2003091229A1 (en)	2002-04-23	2003-04-18	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
NO20044592L true NO20044592L (no)	2004-11-19

Family

ID=29270567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044592A NO20044592L (no)	2002-04-23	2004-10-25	Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer

Country Status (14)

Country	Link
US (1)	US7314876B2 (de)
EP (1)	EP1503996B1 (de)
JP (1)	JP2005529890A (de)
AR (1)	AR039648A1 (de)
AT (1)	ATE418546T1 (de)
AU (1)	AU2003221753A1 (de)
DE (1)	DE60325469D1 (de)
ES (1)	ES2318122T3 (de)
IS (1)	IS7504A (de)
NO (1)	NO20044592L (de)
PE (1)	PE20040411A1 (de)
PL (1)	PL373371A1 (de)
TW (1)	TW200306841A (de)
WO (1)	WO2003091229A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) *	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
US7388009B2 (en)	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
EP1497019B1 (de)	2002-04-23	2015-05-20	Bristol-Myers Squibb Company	Pyrrolo-triazin-anilin-verbindungen als kinaseinhibitoren
JP2005529890A (ja)	2002-04-23	2005-10-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200401638A (en) *	2002-06-20	2004-02-01	Bristol Myers Squibb Co	Heterocyclic inhibitors of kinases
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
WO2004013145A1 (en) *	2002-08-02	2004-02-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200420565A (en) *	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
CA2511970C (en)	2003-01-14	2012-06-26	Cytokinetics, Inc.	Urea derivatives useful in the treatment of heart failure
MXPA05008183A (es)	2003-02-05	2005-10-05	Bristol Myers Squibb Co	Proceso para preparar pirrolotriazina como inhibidores de cinasa.
US20060014741A1 (en) *	2003-12-12	2006-01-19	Dimarco John D	Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en) *	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7652146B2 (en)	2004-02-06	2010-01-26	Bristol-Myers Squibb Company	Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US7459562B2 (en) *	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en)	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
BRPI0512193B8 (pt)	2004-06-17	2021-05-25	Cytokinetics Inc	composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) *	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
TW200600513A (en)	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) *	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7176222B2 (en)	2004-07-27	2007-02-13	Cytokinetics, Inc.	Syntheses of ureas
US7504521B2 (en)	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en)	2004-08-12	2006-06-16	Bristol Myers Squibb Co	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en) *	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
TW200635927A (en) *	2004-12-22	2006-10-16	Bristol Myers Squibb Co	Synthetic process
US7534882B2 (en)	2005-04-06	2009-05-19	Bristol-Myers Squibb Company	Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US7538223B2 (en)	2005-08-04	2009-05-26	Cytokinetics, Inc.	Compounds, compositions and methods
WO2007035428A1 (en)	2005-09-15	2007-03-29	Bristol-Myers Squibb Company	Met kinase inhibitors
US7547782B2 (en)	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7825120B2 (en)	2005-12-15	2010-11-02	Cytokinetics, Inc.	Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
ES2419007T3 (es)	2005-12-15	2013-08-19	Cytokinetics, Inc.	Ciertas entidades químicas, composiciones y procedimientos
US7718657B2 (en)	2005-12-16	2010-05-18	Cytokinetics, Inc.	Certain indanyl urea modulators of the cardiac sarcomere
EP1962852B1 (de)	2005-12-19	2017-01-25	Cytokinetics, Inc.	Verbindungen, zusammensetzungen und verfahren
US8063208B2 (en) *	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
CA2645031A1 (en)	2006-03-07	2007-09-13	Bristol-Myers Squibb Company	Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
EP2376491B1 (de)	2008-12-19	2015-03-04	Cephalon, Inc.	Pyrrolotriazine als alk- und jak2-inhibitoren
WO2012031057A1 (en)	2010-09-01	2012-03-08	Bristol-Myers Squibb Company	Bms- 582949 for the treatment of resistant rheumatic disease
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
WO2019071144A1 (en)	2017-10-05	2019-04-11	Fulcrum Therapeutics, Inc.	USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US20240132521A1 (en)	2022-08-22	2024-04-25	Iambic Therapeutics, Inc.	Compounds and methods for modulating her2

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6147080A (en) *	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
WO1999001452A1 (en) *	1997-07-02	1999-01-14	Smithkline Beecham Corporation	Novel cycloalkyl substituted imidazoles
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
DK1117653T3 (da)	1998-10-01	2003-05-26	Astrazeneca Ab	Quinolin- og quinazolinderivater og deres anvendelse som inhibitorer af cykokin-merierede sygdomme
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
CZ303660B6 (cs) *	1999-05-21	2013-02-13	Bristol-Myers Squibb Company	Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
US6787545B1 (en)	1999-08-23	2004-09-07	Shiongi & Co., Ltd.	Pyrrolotriazine derivatives having spla2-inhibitory activities
GB9924092D0 (en)	1999-10-13	1999-12-15	Zeneca Ltd	Pyrimidine derivatives
RU2264403C2 (ru)	1999-11-10	2005-11-20	Орто-Макнейл Фармасьютикал, Инк.	Замещенные 2-арил-3-(гетероарил) имидазо [1,2-а] пиримидины, содержащие их фармацевтические композиции и связанные с ними способы
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
US6906067B2 (en)	1999-12-28	2005-06-14	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-α expression
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
KR100847605B1 (ko)	2000-11-17	2008-07-21	브리스톨-마이어스스퀴브컴파니	ｐ38 키나제 관련 질병의 치료 방법 및 키나제 억제제로서유용한 피롤로트리아진 화합물
CA2451128A1 (en)	2001-06-26	2003-01-09	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of tnf-alpha expression
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
JP2005529890A (ja)	2002-04-23	2005-10-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US6933386B2 (en)	2002-07-19	2005-08-23	Bristol Myers Squibb Company	Process for preparing certain pyrrolotriazine compounds
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
WO2004013145A1 (en)	2002-08-02	2004-02-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines

2003
- 2003-04-18 JP JP2003587789A patent/JP2005529890A/ja not_active Withdrawn
- 2003-04-18 PL PL03373371A patent/PL373371A1/xx not_active Application Discontinuation
- 2003-04-18 AT AT03718493T patent/ATE418546T1/de not_active IP Right Cessation
- 2003-04-18 TW TW092109124A patent/TW200306841A/zh unknown
- 2003-04-18 EP EP03718493A patent/EP1503996B1/de not_active Expired - Lifetime
- 2003-04-18 DE DE60325469T patent/DE60325469D1/de not_active Expired - Lifetime
- 2003-04-18 AU AU2003221753A patent/AU2003221753A1/en not_active Abandoned
- 2003-04-18 ES ES03718493T patent/ES2318122T3/es not_active Expired - Lifetime
- 2003-04-18 WO PCT/US2003/012420 patent/WO2003091229A1/en not_active Ceased
- 2003-04-22 US US10/420,445 patent/US7314876B2/en not_active Expired - Lifetime
- 2003-04-23 AR ARP030101400A patent/AR039648A1/es unknown
- 2003-04-23 PE PE2003000401A patent/PE20040411A1/es not_active Application Discontinuation
2004
- 2004-10-14 IS IS7504A patent/IS7504A/is unknown
- 2004-10-25 NO NO20044592A patent/NO20044592L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PE20040411A1 (es)	2004-07-14
DE60325469D1 (de)	2009-02-05
IS7504A (is)	2004-10-14
TW200306841A (en)	2003-12-01
ES2318122T3 (es)	2009-05-01
US20030232831A1 (en)	2003-12-18
PL373371A1 (en)	2005-08-22
WO2003091229A1 (en)	2003-11-06
AR039648A1 (es)	2005-03-02
ATE418546T1 (de)	2009-01-15
AU2003221753A1 (en)	2003-11-10
EP1503996A4 (de)	2006-05-17
EP1503996A1 (de)	2005-02-09
JP2005529890A (ja)	2005-10-06
US7314876B2 (en)	2008-01-01
EP1503996B1 (de)	2008-12-24

Legal Events

Date	Code	Title	Description
2008-11-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
GEP20063915B (en)	2006-09-11	PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
NO20025821L (no)	2003-02-04	2-aminokarbonyl-9H-purinderivater
NO20044974L (no)	2004-11-16	Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
GEP20084357B (en)	2008-04-29	Pyrimidine derivatives for the treatment of abnormal cell growth
MY132094A (en)	2007-09-28	Pyrrolo-triazine aniline compounds useful as kinase inhibitors
NO20021328L (no)	2002-05-21	Pyrazolopyrimidier som terapeutiske midler
PL377285A1 (pl)	2006-01-23	Podstawione pochodne pirolo-pirazolowe jako inhibitory kinazy
GB0124933D0 (en)	2001-12-05	Chemical compounds
MY132106A (en)	2007-09-28	New pyridazin-3(2h)-one derivatives
NO20044501L (no)	2005-01-18	[1,4] diazenino [6,7,1-IJ] kinolin-derivater som antipsykotis og antifedme-midler
NO20072399L (no)	2007-08-24	Nye pyrrolo[3,2-d]pyrimidin-4-o-derivater og deres anvendelse i terapi
ATE453639T1 (de)	2010-01-15	Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
NO20076134L (no)	2008-02-29	Benzamidderivater og anvendelser derav
NO20055092L (no)	2005-11-01	Substituerte pyrimidioner
NO20063231L (no)	2006-07-11	Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
NO20075059L (no)	2007-10-08	Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20033145L (no)	2003-09-09	Purinderivater som purinergiske reseptorantagonister
NO20015172L (no)	2002-01-23	1-metyl-erytromycin-derivater
SI1465861T1 (sl)	2009-12-31	Alfa-(n-sulfonamido)acetamidni derivati kot beta-amiloid inhibitorji
MXPA03009750A (es)	2004-06-30	Compuestos quimicos.
GB0308201D0 (en)	2003-05-14	Novel compounds
WO2003082861A3 (en)	2004-03-11	Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
MXPA04000407A (es)	2004-03-18	Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
NO20051892L (no)	2005-06-17	Ny forbindelse
NO20050666L (no)	2005-03-11	2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer